Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 690517 + empagliflozin in heart failure with LVEF ≥40%
ChiCTR2500115369Phase 3Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in heart failure with preserved ejection fraction (HFpEF) and heart failure with mid-range ejection fraction (HFmrEF) comparing BI 690517 + empagliflozin with Placebo + empagliflozin (2 arms). Primary endpoint: Time to first event of cardiovascular death or hospitalization for heart failure (HHF). Started Dec 2025; status: recruiting.
02
Drugs
vicadrostat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on ChiCTR2500115369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115369.